Prospects for use of Vericiguat in HFrEF : Implications of VICTORIA Trial Results. Advisory Board Summary
In September 2021, an online meeting of the Council of Experts was held. The proposed focus of discussion was publishing the results of an international prospective, randomized, double-blind, placebo-controlled study VICTORIA. The objective of the VICTORIA study was evaluation of the efficacy and safety of supplementing a standard therapy with vericiguat at a target dose of 10 mg twice a day as compared to placebo for prevention of cardiovascular death and hospitalization for heart failure (HF) in patients with clinical manifestations of chronic HF and left ventricular ejection fraction <45% who have recently had an episode of decompensated HF. The aim of the meeting was interpretation of the VICTORIA study results on efficacy and safety of vericiguat for a potential use in a Russian population of patients after a recent episode of decompensated chronic HF with reduced ejection fraction.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:63 |
|---|---|
| Enthalten in: |
Kardiologiia - 63(2023), 4 vom: 01. Mai, Seite 3-10 |
| Sprache: |
Russisch |
|---|
| Beteiligte Personen: |
Belenkov, Yu N [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
English Abstract |
|---|
| Anmerkungen: |
Date Completed 13.05.2023 Date Revised 13.05.2023 published: Electronic Citation Status MEDLINE |
|---|
| doi: |
10.18087/cardio.2023.4.n2403 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM356688895 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM356688895 | ||
| 003 | DE-627 | ||
| 005 | 20231226071006.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||rus c | ||
| 024 | 7 | |a 10.18087/cardio.2023.4.n2403 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1188.xml |
| 035 | |a (DE-627)NLM356688895 | ||
| 035 | |a (NLM)37165988 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a rus | ||
| 100 | 1 | |a Belenkov, Yu N |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Prospects for use of Vericiguat in HFrEF |b Implications of VICTORIA Trial Results. Advisory Board Summary |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 13.05.2023 | ||
| 500 | |a Date Revised 13.05.2023 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a In September 2021, an online meeting of the Council of Experts was held. The proposed focus of discussion was publishing the results of an international prospective, randomized, double-blind, placebo-controlled study VICTORIA. The objective of the VICTORIA study was evaluation of the efficacy and safety of supplementing a standard therapy with vericiguat at a target dose of 10 mg twice a day as compared to placebo for prevention of cardiovascular death and hospitalization for heart failure (HF) in patients with clinical manifestations of chronic HF and left ventricular ejection fraction <45% who have recently had an episode of decompensated HF. The aim of the meeting was interpretation of the VICTORIA study results on efficacy and safety of vericiguat for a potential use in a Russian population of patients after a recent episode of decompensated chronic HF with reduced ejection fraction | ||
| 650 | 4 | |a Randomized Controlled Trial | |
| 650 | 4 | |a English Abstract | |
| 650 | 4 | |a Journal Article | |
| 650 | 7 | |a vericiguat |2 NLM | |
| 650 | 7 | |a LV66ADM269 |2 NLM | |
| 700 | 1 | |a Arutyunov, G P |e verfasserin |4 aut | |
| 700 | 1 | |a Mareev, V Yu |e verfasserin |4 aut | |
| 700 | 1 | |a Koziolova, N A |e verfasserin |4 aut | |
| 700 | 1 | |a Sitnikova, M Yu |e verfasserin |4 aut | |
| 700 | 1 | |a Ageev, F T |e verfasserin |4 aut | |
| 700 | 1 | |a Gilyarevsky, S R |e verfasserin |4 aut | |
| 700 | 1 | |a Chesnikova, A I |e verfasserin |4 aut | |
| 700 | 1 | |a Yakushin, S S |e verfasserin |4 aut | |
| 700 | 1 | |a Perepech, N B |e verfasserin |4 aut | |
| 700 | 1 | |a Mareev, Yu V |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Kardiologiia |d 1961 |g 63(2023), 4 vom: 01. Mai, Seite 3-10 |w (DE-627)NLM000007153 |x 0022-9040 |7 nnns |
| 773 | 1 | 8 | |g volume:63 |g year:2023 |g number:4 |g day:01 |g month:05 |g pages:3-10 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.18087/cardio.2023.4.n2403 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 63 |j 2023 |e 4 |b 01 |c 05 |h 3-10 | ||